Clinical Evaluation of Thiamidol-containing Formulations for the Visual Management of Facial Hyperpigmentation
Main Article Content
Keywords
Thiamidol, Hyperpigmentation
Abstract
Objective: Skin hyperpigmentation, which includes melasma, post-inflammatory hyperpigmentation, and solar lentigines, significantly impacts patients’ quality of life. The overproduction of melanin occurs via a complex mechanism and is mediated by activation of the human skin enzyme tyrosinase through conversion of L-Dopa to the end product melanin with subsequent deposition in skin. Thiamidol-based formulations have been previously shown to be effective in reducing the visible factors associated with this human skin enzyme. The objective of this research was to investigate the clinical efficacy of a novel cosmetic Thiamidol-containing serum and Thiamidol-containing regimen (Day Lotion with SPF 30, Serum, and Night Cream) for the visible management of facial hyperpigmentation.
Materials and Methods: A randomized study was performed with 90 subjects (representative of Fitzpatrick Skin Types I-VI) clinically presenting with facial hyperpigmentation as measured by colorimeter and individual typology angle (ITA0) (Thiamidol serum n=43; Thiamidol regimen n=47), to assess the efficacy of a Thiamidol-based serum (2x daily application; morning/night) or a Thiamidol-based regimen (Day lotion with SPF 30 + Serum in morning; Night cream + Serum at night) for 12 weeks with a 6-week regression period. Assessments of skin lightness (L*), ITA0 value, radiance, and shine were conducted at baseline, Weeks 2, 4, 8, 12, and 18.
Results: A significant visible reduction in facial hyperpigmentation, assessed by increases in L* and ITA° values, along with an increase in skin radiance and shine, were observed as early as Week 2, with continued improvement through Week 12 in both the Serum and Regimen groups relative to baseline. At Week 12, changes in radiance and shine were trending toward enhancement in the regimen group compared to serum group.
Discussion: This study demonstrates the clinical effectiveness of Thiamidol-containing formulations in the visible improvement of facial hyperpigmentation and in overall skin radiance and shine. These data support the use of Thiamidol-containing formulations as part of the overall management strategy for individuals affected by facial hyperpigmentation.
Scientific Poster support provided by Beiersdorf, Inc.
References
2. Kerob D, Passeron T, Alexis A, et al. J Am Acad Dermatol. 2024;91(3)(AB73).
3. Mann T, Gerwat W, Batzer J, et al. J Invest Dermatol. 2018;138(7):1601-1608.
4. Hearing VJ, Jr., Ekel TM, Montague PM, Nicholson JM. Biochim Biophys Acta. 1980;611(2):251-268.
5. Vachiramon V, Kositkuljorn C, Leerunyakul K, Chanprapaph K. J Cosmet Dermatol. 2021;20(3):987-992.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.